Cargando…
Factors Associated With Relapse and Treatment of Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease in the United Kingdom
IMPORTANCE: Longer-term outcomes and risk factors associated with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) are not well established. OBJECTIVE: To investigate longer-term risk of relapse and factors associated with this risk among patients with MOGAD. DESIGN, SETTING,...
Autores principales: | Satukijchai, Chanjira, Mariano, Romina, Messina, Silvia, Sa, Mario, Woodhall, Mark R., Robertson, Neil P., Ming, Lim, Wassmer, Evangeline, Kneen, Rachel, Huda, Saif, Jacob, Anu, Blain, Camilla, Halfpenny, Christopher, Hemingway, Cheryl, O'Sullivan, Eoin, Hobart, Jeremy, Fisniku, Leonora K., Martin, Roswell, Dopson, Ruth, Cooper, Sarah A., Williams, Victoria, Waters, Patrick J., Ramdas, Sithara, Leite, Maria Isabel, Palace, Jacqueline |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8749481/ https://www.ncbi.nlm.nih.gov/pubmed/35006246 http://dx.doi.org/10.1001/jamanetworkopen.2021.42780 |
Ejemplares similares
-
Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children
por: Hacohen, Yael, et al.
Publicado: (2015) -
Case Report: Myelin Oligodendrocyte Glycoprotein Antibody-Associated Relapse With COVID-19
por: Woodhall, Mark, et al.
Publicado: (2020) -
Chronic relapsing inflammatory optic neuropathy (CRION): a manifestation of myelin oligodendrocyte glycoprotein antibodies
por: Lee, Haeng-Jin, et al.
Publicado: (2018) -
Comparison of Clinical Outcomes of Transverse Myelitis Among Adults With Myelin Oligodendrocyte Glycoprotein Antibody vs Aquaporin-4 Antibody Disease
por: Mariano, Romina, et al.
Publicado: (2019) -
Serial Anti–Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes
por: Waters, Patrick, et al.
Publicado: (2019)